US FDA grants Breakthrough Therapy designation to haemophilia A treatment
The new investigational recombinant factor VIII (FVIII) therapy efanesoctocog alfa has been designed to extend protection from bleeds with once-weekly prophylactic dosing for haemophilia A patients. It is